文献速递乳腺癌

一例HER2突变驱动乳腺癌患者获得性HER2T798I守门突变导致来那替尼耐药

An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.
PubMed 文献 · Cancer Discov · 2017-03-08

报告一例HER2L869R突变乳腺癌患者在接受来那替尼治疗获得性耐药后出现HER2T798I守门突变。实验室研究提示HER2L869R为来那替尼敏感的功能获得性突变,与突变型HER3E928G二聚化后放大HER2信号。患者接受来那替尼治疗并获得持续部分缓解,临床进展时在血浆肿瘤游离DNA中检测到HER2T798I。结构建模提示HER2T798I中异亮氨酸体积增大降低来那替尼结合。来那替尼阻断表达HER2L869R但不阻断HER2L869R/T798I细胞的HER2介导信号和生长,而阿法替尼和奥希替尼代谢物AZ5104强烈抑制HER2L869R/T798I诱导的信号和细胞生长。

要点

  • HER2L869R突变乳腺癌患者来那替尼治疗后获得持续部分缓解,进展时血浆游离DNA检出HER2T798I。
  • 来那替尼抑制表达HER2L869R细胞的HER2信号和生长,但不抑制表达HER2L869R/T798I的细胞。
  • 阿法替尼和奥希替尼代谢物AZ5104强烈抑制HER2L869R/T798I诱导的信号和细胞生长。

核心结论

  • 在初始携带激活型HER2突变的乳腺癌中,来那替尼耐药出现后获得HER2T798I,提示HER2L869R为驱动突变。
  • HER2T798I介导的来那替尼耐药可能被其他不可逆HER2抑制剂如阿法替尼克服。

研究设计与样本

  • 病例报告结合实验室研究:一例HER2L869R突变乳腺癌患者接受来那替尼治疗,出现获得性耐药后检测血浆肿瘤游离DNA。
  • 实验室研究评估HER2L869R及HER2L869R/T798I突变对来那替尼、阿法替尼和奥希替尼代谢物AZ5104的敏感性,并进行结构建模。

主要发现

  • 患者接受来那替尼治疗并获得持续部分缓解,临床进展时在血浆肿瘤游离DNA中检测到HER2T798I。
  • 实验室研究提示HER2L869R为来那替尼敏感的功能获得性突变,与突变型HER3E928G二聚化后放大HER2信号。
  • 结构建模提示HER2T798I中异亮氨酸体积增大降低来那替尼结合。
  • 来那替尼阻断表达HER2L869R细胞的HER2介导信号和生长,但不阻断表达HER2L869R/T798I的细胞。
  • 阿法替尼和奥希替尼代谢物AZ5104强烈抑制HER2L869R/T798I诱导的信号和细胞生长。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report a HER2T798I gatekeeper mutation in a patient with HER2L869R-mutant breast cancer with acquired resistance to neratinib. Laboratory studies suggested that HER2L869R is a neratinib-sensitive, gain-of-function mutation that upon dimerization with mutant HER3E928G, also present in the breast cancer, amplifies HER2 signaling. The patient was treated with neratinib and exhibited a sustained partial response. Upon clinical progression, HER2T798I was detected in plasma tumor cell-free DNA. Structural modeling of this acquired mutation suggested that the increased bulk of isoleucine in HER2T798I reduces neratinib binding. Neratinib blocked HER2-mediated signaling and growth in cells expressing HER2L869R but not HER2L869R/T798I In contrast, afatinib and the osimertinib metabolite AZ5104 strongly suppressed HER2L869R/T798I-induced signaling and cell growth. Acquisition of HER2T798I upon development of resistance to neratinib in a breast cancer with an initial activating HER2 mutation suggests HER2L869R is a driver mutation. HER2T798I-mediated neratinib resistance may be overcome by other irreversible HER2 inhibitors like afatinib.Significance: We found an acquired HER2 gatekeeper mutation in a patient with HER2-mutant breast cancer upon clinical progression on neratinib. We speculate that HER2T798I may arise as a secondary mutation following response to effective HER2 tyrosine kinase inhibitors (TKI) in other cancers with HER2-activating mutations. This resistance may be overcome by other irreversible HER2 TKIs, such as afatinib. Cancer Discov; 7(6); 575-85. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 539.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Hanker AB, Brewer MR, Sheehan JH, et al. An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. Cancer Discov. 2017. PMID: 28274957. doi:10.1158/2159-8290.CD-16-1431

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。